DK0923941T3 - Midler mod myelom der skal anvendes sammen med nitrogensennepantitumormidler - Google Patents

Midler mod myelom der skal anvendes sammen med nitrogensennepantitumormidler

Info

Publication number
DK0923941T3
DK0923941T3 DK97928507T DK97928507T DK0923941T3 DK 0923941 T3 DK0923941 T3 DK 0923941T3 DK 97928507 T DK97928507 T DK 97928507T DK 97928507 T DK97928507 T DK 97928507T DK 0923941 T3 DK0923941 T3 DK 0923941T3
Authority
DK
Denmark
Prior art keywords
agents
myeloma
nitrogen mustard
conjunction
receptor antibody
Prior art date
Application number
DK97928507T
Other languages
Danish (da)
English (en)
Inventor
Akito Chugai Seiyaku Nakamura
Kenichi Chugai Seiyak Akamatsu
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK0923941T3 publication Critical patent/DK0923941T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK97928507T 1996-06-27 1997-06-27 Midler mod myelom der skal anvendes sammen med nitrogensennepantitumormidler DK0923941T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16732596 1996-06-27

Publications (1)

Publication Number Publication Date
DK0923941T3 true DK0923941T3 (da) 2006-09-18

Family

ID=15847661

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97928507T DK0923941T3 (da) 1996-06-27 1997-06-27 Midler mod myelom der skal anvendes sammen med nitrogensennepantitumormidler

Country Status (10)

Country Link
US (3) US6692742B1 (de)
EP (1) EP0923941B1 (de)
JP (1) JP3471195B2 (de)
AT (1) ATE326238T1 (de)
AU (1) AU3276297A (de)
DE (1) DE69735888T2 (de)
DK (1) DK0923941T3 (de)
ES (1) ES2263178T3 (de)
PT (1) PT923941E (de)
WO (1) WO1997049428A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049428A1 (fr) * 1996-06-27 1997-12-31 Chugai Seiyaku Kabushiki Kaisha Remedes contre les myelomes a utiliser en combinaison avec des agents anti-tumoraux a base d'azote de la moutarde
EP2322216A1 (de) 1997-03-21 2011-05-18 Chugai Seiyaku Kabushiki Kaisha Präventives oder therapeutisches Mittel mit einem IL-6-Antagonisten als Wirkstoff für durch sensibilisierte T-Zellen vermittelte Erkrankungen
DK1113810T3 (da) * 1998-09-14 2009-04-06 Univ Texas Fremgangsmåder til behandling af multipelt myelom og myelom-induceret knogleresorption under anvendelse af antagonister af integrin/receptor-binding
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
EP1475101B1 (de) * 2002-02-14 2010-10-27 Chugai Seiyaku Kabushiki Kaisha Antikörper enthaltende pharmazeutische lösungen
WO2004000229A2 (en) * 2002-06-24 2003-12-31 Research Development Foundation Treatment of human multiple myeloma by curcumin
JP5525118B2 (ja) 2002-09-11 2014-06-18 中外製薬株式会社 タンパク質精製方法
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
JP2007503475A (ja) 2003-08-26 2007-02-22 リサーチ ディベロップメント ファウンデーション 破骨細胞形成阻害剤およびその使用方法
ES2368741T3 (es) * 2004-02-25 2011-11-21 Dana-Farber Cancer Institute, Inc. Inhibidores del receptor 1 del factor de crecimiento de tipo insulina para inhibir el crecimiento de células tumorales.
EP1728801A4 (de) * 2004-03-24 2009-10-21 Chugai Pharmaceutical Co Ltd Subtyp eines humanisierten antikörpers gegen den interleukin-6-rezeptor
AU2006210746B2 (en) * 2005-02-03 2012-04-26 Topotarget Uk Limited Combination therapies using HDAC inhibitors
US7872050B2 (en) * 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US20110039943A1 (en) * 2005-03-14 2011-02-17 Robert Alonso Methods for treating skin disorders with topical nitrogen mustard compositions
US8501818B2 (en) * 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
MY159787A (en) * 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
ES2543201T3 (es) * 2007-12-26 2015-08-17 Biotest Ag Métodos y agentes que mejoran la dirección a las células tumorales que expresan CD138
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
LT2273876T (lt) 2008-03-27 2019-05-27 Helsinn Healthcare Sa Stabilizuotos alkilinimo medžiagų kompozicijos ir jų panaudojimo būdai
DK2493922T3 (en) 2009-10-26 2017-04-24 Hoffmann La Roche Process for preparing a glycosylated immunoglobulin
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
KR20200059320A (ko) 2010-11-08 2020-05-28 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
RU2604139C2 (ru) 2011-01-28 2016-12-10 Санофи Байотекнолоджи Фармацевтические композиции, содержащие антитела к pcsk9 человека
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
CN104302324A (zh) 2011-12-08 2015-01-21 生物测试股份公司 靶向cd138的免疫偶联物的用途
SG10201610869TA (en) 2012-06-26 2017-02-27 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
CN105378480B (zh) 2013-07-04 2018-06-12 豪夫迈·罗氏有限公司 检测血清样品中抗药物抗体的干扰抑制性免疫测定
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
CA2995645A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
WO2017147169A1 (en) 2016-02-22 2017-08-31 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
AU2018234844B2 (en) 2017-03-17 2024-01-25 Ohio State Innovation Foundation Nanoparticles for delivery of chemopreventive agents
CN114206442A (zh) 2019-01-31 2022-03-18 赛诺菲生物技术公司 用于治疗幼年特发性关节炎的抗il-6受体抗体
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
SG42954A1 (en) * 1989-07-20 1997-10-17 Tadamitsu Kishimoto Antibody to human interleukin-6 receptor
DE69229482T2 (de) * 1991-04-25 1999-11-18 Chugai Seiyaku K.K., Tokio/Tokyo Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor
US5882941A (en) * 1994-05-04 1999-03-16 Massachusette Institute Of Technology Programmable genotoxic agents and uses therefor
WO1997049428A1 (fr) * 1996-06-27 1997-12-31 Chugai Seiyaku Kabushiki Kaisha Remedes contre les myelomes a utiliser en combinaison avec des agents anti-tumoraux a base d'azote de la moutarde
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer

Also Published As

Publication number Publication date
JP3471195B2 (ja) 2003-11-25
AU3276297A (en) 1998-01-14
US7566453B2 (en) 2009-07-28
US20040247621A1 (en) 2004-12-09
ATE326238T1 (de) 2006-06-15
WO1997049428A1 (fr) 1997-12-31
DE69735888T2 (de) 2006-11-02
PT923941E (pt) 2006-09-29
DE69735888D1 (de) 2006-06-22
ES2263178T3 (es) 2006-12-01
JPH1087510A (ja) 1998-04-07
EP0923941A4 (de) 2001-12-05
US20020131967A1 (en) 2002-09-19
US6692742B1 (en) 2004-02-17
EP0923941A2 (de) 1999-06-23
EP0923941B1 (de) 2006-05-17
US7771723B2 (en) 2010-08-10

Similar Documents

Publication Publication Date Title
DK0923941T3 (da) Midler mod myelom der skal anvendes sammen med nitrogensennepantitumormidler
TR200002759T2 (tr) Bacak uyuşması sendromunun tedavisinde kabergolin kullanımı.
DE4494132T1 (de) Funktelefongerät mit drahtlosem Kopfhörer
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
DK0712931T4 (da) Interferon-gamma-produktionsinducerende polypeptid, monoklonalt antistof og middel mod sygdomme, der responderer på interferon-gamma
DZ2043A1 (fr) Nouveaux dérivés.
ATE238289T1 (de) Synthese von taxol und deren derivate
EE04752B1 (et) Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine
ATE334718T1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
PL357944A1 (en) Intradermal-penetration agents for topical local anesthetic administration
TR200002179T2 (tr) Kristalin teriparatid.
BR9303469A (pt) Conjugado de interferon,composto,processo de preparacao de um conjugado de interferon,use e composicoes farmaceuticas
DK0971717T3 (da) Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler
DK2689A (da) Farmaceutisk praeparat
PH23222A (en) Immunoglobulin conjugates and pharmaceutical formulation thereof
ES2140489T3 (es) Receptor de interferona soluble, su preparacion y su uso.
IL126109A0 (en) Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
TR200001288T2 (tr) Östrojen yoksunluğu sendromunun tedavisinde faydalı 2-arilbenzo (b) tiyofenler.
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
DK0784613T3 (da) Colchicinderivater og den terapeutiske anvendelse deraf
DK643587D0 (da) I det vaesentlige rent praeparat af et enzym/antistof-konjugat, dets fremstilling og anvendelse.
DK694188A (da) Anvendelse af ace-inhibitor til laegemiddelfremstilling, evt. i kombination med et calciumkanalblokeringsmiddel
ID26703A (id) Penggunaan anestesi lokal untuk sakit kepala vaskular
DE69827017D1 (de) Kombinationen von endometrium schonenden gestagenen und endometrium atrophisierenden gestagenen mit estrogenen, bei der oralen empfängnisverhütung
FI961339A (fi) Triaryylieteenijohdannaiset käytettäväksi hoidossa